icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

‘Just like a flu shot': People may need to take Covid-19 vaccine annually ‘for the next several years’, says Johnson & Johnson CEO

‘Just like a flu shot': People may need to take Covid-19 vaccine annually ‘for the next several years’, says Johnson & Johnson CEO
Alex Gorsky, CEO of Johnson & Johnson, has said people may need Covid-19 vaccines annually for the next several years following his company applying for emergency use authorization for its own one-dose shot.

In a Tuesday interview with CNBC, Gorsky said it’s “likely” that “for the next several years, we’ll be getting a COVID-19 shot just like we would a flu shot.”

In this near future, Gorsky sees science keeping “pace” with the virus, but vaccines will allow people to “keep on living [their] lives.”

Johnson & Johnson could be introducing their Covid vaccine as early as this month. They applied for emergency use authorization from the US Food and Drug Administration (FDA) last Thursday, and the body’s advisory panel is set to make a recommendation about whether or not to greenlight the inoculation on February, 26.

A perceived benefit to their vaccine, in comparison to the already available ones from Pfizer and Moderna, is that it takes only one dose, as opposed to two given weeks apart. 

Also on rt.com Fear of Covid-19 no longer petrifies 1 in 3 Americans, but indecision about how to move forward does

Early data, however, has suggested it might not offer as strong of protection as the competitors. A study conducted with 44,000 people in the US, Latin America, and South Africa found that while the vaccine was 85 percent effective at preventing severe cases of Covid-19, it has shown 72 percent effectiveness against both moderate and severe cases in the US trial, and 66 percent effectiveness against moderate and severe cases overall.

Mutations to the virus, Gorsky told CNBC, means the public will need to be vigilant with taking vaccines, and future secondary vaccines may be needed. 

“Unfortunately, as [the virus] spreads it can also mutate,” he said. “Every time it mutates, it’s almost like another click of the dial so to speak where we can see another variant, another mutation that can have an impact on its ability to fend off antibodies or to have a different kind of response not only to a therapeutic but also to a vaccine.”

Gorsky said his company is working “full speed” on getting authorization for their vaccine. The Department of Health and Human Services entered an agreement with Janssen Biotech, the company’s pharmaceutical subsidiary, in August of last year for 100 million doses of their vaccine, which Gorsky said can be delivered by June.

If you like this story, share it with a friend!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.

Podcasts